Treating women with opioid use disorder during pregnancy in Appalachia: Initial neonatal outcomes following buprenorphine + naloxone exposure
Linda Nguyen, Laura R Lander, Kevin E O'Grady, Patrick J Marshalek, Adrienne Schmidt, Audra K Kelly, Hendrée E Jones, Linda Nguyen, Laura R Lander, Kevin E O'Grady, Patrick J Marshalek, Adrienne Schmidt, Audra K Kelly, Hendrée E Jones
Abstract
Background and objectives: Rising concerns regarding diversion and misuse of mono-buprenorphine for treatment of pregnant women with opioid use disorders have sparked interest in the use of buprenorphine + naloxone to reduce misuse and diversion rates. Examined the relationship of prenatal buprenorphine + naloxone exposure to neonatal outcomes.
Methods: This is a retrospective chart review of 26 mother infant dyads in comprehensive medication-assisted treatment with buprenorphine + naloxone during pregnancy.
Results: All neonatal birth outcome parameters were within normal ranges, albeit on the lower side of normal for gestational age and birth weight. Only 19% of neonates required morphine pharmacology for NAS.
Conclusions: Use of buprenorphine + naloxone shows relative safety in pregnancy.
Scientific significance: These findings can help better guide prescribing practices for pregnant patients at risk for misuse or diversion of buprenorphine. (Am J Addict 2018;27:92-96).
Conflict of interest statement
Declaration of Interest
The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this paper.
© 2018 American Academy of Addiction Psychiatry.
Source: PubMed